ViaDerma Investor Information

Overview

ViaDerma, Inc. (OTC Pink: VDRM) is a pharmaceutical company committed to bringing new products to the pharmaceutical industry through innovative research and development.
ViaDerma manufactures and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The Company’s lead products Vitastem & Vitastem Ultra are normally applied topically using a patent-pending topical delivery system technology.
Presently, the Vitastem first aid & topical antibiotic product is used within the OTC drug market, i.e. non-prescription. ViaDerma believes the delivery system can be used for the prescription medication market as well not only for topical prescription medications but also to turn certain oral medications into topically based medications.
In addition to the primary plan of developing and selling new products to the market, ViaDerma is exploring the possibility of licensing the technology to other industry leading pharmaceutical companies around the world.

Financials

Latest financial disclosures available here on OTCmarkets.com

Security Details

Authorized Shares Outstanding Shares RestrictedUnrestricted Held at DTC Float Par Value
1,250,000,000 02/03/2023 1,023,620,662 02/03/2023 69,456,186 02/03/2023954,164,476 02/03/2023952,931,395 02/03/2023911,600,265 07/23/20210.001

See VDRM security details on OTCmarkets.com

Disclosures

12/15/2022: Quarterly Report – Quarterly Report

11/15/2022: Notification of Late Filing – Notification of Late Filing

10/17/2022: Quarterly Report – Quarterly Report

05/12/2022: Quarterly Report – Quarterly Report

05/01/2022: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information

03/29/2022: Annual Report – Annual Report

12/20/2021: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information

11/12/2021: Quarterly Report – Quarterly Report

10/18/2021: Attorney Letter with Respect to Current Information – Attorney Letter with Respect to Current Information

08/24/2021: Annual Report – Amended and Restated

 

Latest financial disclosures available here on OTCmarkets.com

Developing & Licensing the World’s Strongest, Most Effective Broad-Spectrum Antibiotics for Infectious Skin Diseases and Wound Care.

Copyright: © ViaDerma, Inc. 2024